Udenafil

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Udenafil
Udenafil.svg
Clinical data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • US: Not approved
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding 93,9%
Metabolism Liver (mainly CYP3A4)
Elimination half-life 7.3–12.1 hours
Excretion Biliary
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C25H36N6O4S
Molar mass 516.657 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

The drug udenafil is marketed under the trade name Zydena. It is within the PDE5 inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Like other PDE5 inhibitors, it is used to treat erectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical.[1] It has fairly rapid onset of action (peak plasma concentration after 1 to 1.5 hours), and has long duration of action (plasma half life of 11 to 13 hours). Udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use).[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines.[3] It has not yet been approved for use in the United States by the U.S. Food and Drug Administration.

References[edit]

  1. ^ Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
  2. ^ Kang, SG; Kim, JJ (2013). "Udenafil: efficacy and tolerability in the management of erectile dysfunction". Ther Adv Urol. 5: 101–10. doi:10.1177/1756287212470019. PMC 3607490Freely accessible. PMID 23554845. 
  3. ^ "Zydena", Drugs.com